» Articles » PMID: 8726152

Aerosol Deposition in Infants with Cystic Fibrosis

Overview
Date 1996 May 1
PMID 8726152
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty asymptomatic infants with cystic fibrosis (CF) were studied to determine the amount of radiolabeled aerosol [99m technetium diethylenetriamine penta acetic acid (Tc99m DTPA)] deposited in the respiratory system and its distribution. Aerosols were generated by jet nebulization systems that were used in the wards and the laboratory. Subjects were studied in three groups: group A (n = 10) was sedated with chloral hydrate; children inhaled an aerosol of 7.7 microns mass median diameter (MMD); group B (n = 5) was not sedated, using the same nebulization system (same aerosol particle size as group A); and group C (n = 5) was not sedated; these children inhaled an aerosol with an MMD of 3.6 microns. Normal saline plus 4 mCi of Tc99m bound to DTPA was added to each nebulizer. A closed system was used to collect the expired aerosol. Radioactivity in each infant and in the equipment was measured with a gamma camera on completion of nebulization. In groups A and B, the percentages of the total dose deposited in the lung were 0.97 +/- 0.35% and 0.76 +/- 0.36%, respectively. In group C, 2.0 +/- 0.71% was deposited in the lung (P < 0.01). Deposition in the nose, mouth, and pharynx was least in group C (P < 0.01). In groups A and B, the intrathoracic deposition occurred predominantly in the trachea and main bronchi, whereas in group C, significantly more aerosol was deposited in the lung region. There was marked inter-subject variability in the percentage of aerosol deposition within the three groups. There was no correlation between percentage of aerosol deposited in the respiratory system and age, height, or weight. Sedation did not have a significant effect on deposition of aerosol in infants. This study indicates that only a small proportion of nebulized solution is deposited in the lungs of infants and that this proportion is influenced by the particle size of the aerosol. The smaller particle size (3.6 microns MMD) was deposited in the lung better than large particles.

Citing Articles

Development of an Infant Air-Jet Dry Powder Aerosol Delivery System (iDP-ADS) Including a New Multifunctional Bifurcating Two-Prong Nasal Interface.

Strickler S, Farkas D, Momin M, Vargas L, Aladwani G, Hindle M Pharm Res. 2025; 42(2):365-384.

PMID: 39930310 PMC: 11880044. DOI: 10.1007/s11095-024-03814-y.


Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.

Jubaer H, Strickler S, Farkas D, Dalton C, Momin M, Dodson K AAPS PharmSciTech. 2025; 26(1):34.

PMID: 39821052 DOI: 10.1208/s12249-024-02987-4.


Nebuliser systems for drug delivery in cystic fibrosis.

Stanford G, Morrison L, Brown C Cochrane Database Syst Rev. 2023; 11:CD007639.

PMID: 37942828 PMC: 10633867. DOI: 10.1002/14651858.CD007639.pub3.


Advancement of a high-dose infant air-jet dry powder inhaler (DPI) with passive cyclic loading: Performance tuning for different formulations.

Howe C, Momin M, Aladwani G, Strickler S, Hindle M, Longest W Int J Pharm. 2023; 643:123199.

PMID: 37406945 PMC: 10530264. DOI: 10.1016/j.ijpharm.2023.123199.


Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the Formulation.

Howe C, Momin M, Aladwani G, Hindle M, Longest P Pharm Res. 2022; 39(12):3317-3330.

PMID: 36253630 PMC: 10561662. DOI: 10.1007/s11095-022-03409-5.